chrisvoncsefalvay/vaers-outcomes huggingface dataset:
had titers drawn/ did not present enough antibodies for measles; Information has been received from a physician via a field representative referring to a 24 years old female patient without pregnancy. Information about medical history, concurrent condition and concomitant medication was unknown.        On an unknown date (reported as "year ago"), the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) (strength, dose, frequency, route, lot# and expiration date were unspecified) for prophylaxis. On an unspecified date in 2019 (reported as "recently"), the patient had titers drawn and did not present enough antibodies for measles. The patient did not seek medical attention and it was unknown if treatment was given for the event. The outcome of titers drawn/ not present enough antibodies for measles and the causality were unknown.  This is one of three reports received from the same reporter.; Sender's Comments:  US-009507513-1905USA006158: US-009507513-1905USA006157:
Employee reported itching on right arm at vaccine site. When evaluated an erythematic area measuring 6cms was found at vaccine site, R arm.
Meningococcal conjugate vaccine (Menactra) given (dose #3), instead of Bexsero (Meningococcal Group B Vaccine-dose #2) by another Nurse.  No adverse reactions noted or reported.
6/24/09 redness, swelling, warmth, soreness below sight of varicella immu Dx "Mild Superficial Cellulitis". Rx KEFLEX 500 mg po BID x 10d. 6/25/09 increased redness c/o painful thigh no streaking. Rx ROCEPHIN 1 Gm L buttocks D/C KEFLEX CBC WNL. 6/26/09 leg looking much better she is feeling better.
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. On 15-AUG-2016, the patient was vaccinated with incorrectly stored dose of M-M-R II lot # reported as L026553, therapy type was not specified (dose and route of administration were not reported). This is one of several reports received from the same source. Additional information has been requested.
Around 8 hours after the vaccine, I started to feel very cold.  At around 16 hours I measured a temperature of 100.13 deg. F.  Also a slight headache, and soreness near the injection site.
This spontaneous report was received from a medical assistant, concerning a patient of unknown age and gender. The patient's medical history, concurrent conditions, drug reactions, allergies and concomitant medications were not reported. Between 01-AUG-2018 and 06-AUG-2018, the patients were vaccinated with an improperly stored VARIVAX subcutaneously, for prophylaxis, lot #N035940 and expiration date 18-DEC-2019 (strength, dose and frequency were not reported), which was reconstituted with a properly stored sterile diluent (MERCK). No adverse effects were reported. The temperatures of excursion were reported as 6°F to 14°F during a time frame of 1 hour and 15 minutes and 28.5°F during a time frame of 45 minutes. There was no previous temperature excursion reported. There was a digital data logger involved. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1808USA009440: US-009507513-1808USA009441: US-009507513-1808USA009442: US-009507513-1808USA009443: US-009507513-1808USA009445: US-009507513-1808USA009446: US-009507513-1808USA009447: US-009507513-1808USA003515.
Severe sores developed in mouth, starting with a canker sore that moved to tongue around three days after onset of first symptom. Geographic tongue developed shortly after with more canker sores under tongue. Symptoms are began to clear up after 7 days of onset. Prescribed special mouthwash compound to help with swelling and pain.
Idiopathic hypereosinophilic syndrome; This literature-non-study case was reported in a literature article and describes the occurrence of HYPEREOSINOPHILIC SYNDROME (Idiopathic hypereosinophilic syndrome) in a 23-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.       Concurrent medical conditions included Asthma.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced HYPEREOSINOPHILIC SYNDROME (Idiopathic hypereosinophilic syndrome) (seriousness criterion medically significant). At the time of the report, HYPEREOSINOPHILIC SYNDROME (Idiopathic hypereosinophilic syndrome) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant and treatment medications were not provided.   Authors stated that hypereosinophilia may occur rarely following COVID-19 vaccination and would be considered in patients presenting with symptoms consistent with eosinophilic disease. This may be due to Th2-skewing, a phenomenon observed in vaccine associated enhanced disease which had occurred with other vaccines.  Company comment: This is a literature non-study case concerning a 23-year-old, female patient with a concurrent medical condition of Asthma, who experienced the serious (due to medically significant) unexpected, event of Hypereosinophilic syndrome reported as Idiopathic hypereosinophilic syndrome. The event occurred approximately 1 week after the second dose of mRNA-1273 vaccine. The outcome of the event was reported as unknown. The mentioned medical condition of Asthma remains as a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   This case was linked to US-MODERNATX, INC.-MOD-2023-708167, US-MODERNATX, INC.-MOD-2023-708168 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-708168:Adult Patient 2 US-MODERNATX, INC.-MOD-2023-708167:Adult Patient 1
Eye swelling - 10:30 AM - took BENADRYL. Vomiting/diarrhea 12:30 PM.
Pt had hard knot at injection site slight fever and chills little headache on 1st night. 2nd day slept a lot red rash and swelling about 1 and 1/2 inches below injection site on inside of bicep and sore on days 2 and 3.
On 11/5/99, the pt developed pain, swelling, and redness at injection site and on entire upper arm from left elbow to shoulder. On 11/8/99, the pt was seen by a physician.
Narrative: COVID infection following completion of COVID vaccine series 02/02/21 COVID vaccine dose #1 03/02/21 COVID vaccine dose #2 07/26/21 Pt presents to clinic reporting foul smelling white discharge; rx given for metronidazole and clotrimazole 07/28/21 Pt presents to screening reporting cough, fever, muscle pain, runny nose, sinus congestion; COVID POSITIVE 07/30/21 Pt reports improved chills, fatigue, headache, and runny nose; reports productive cough, muscle pain, shortness of breath; rx give for zinc 08/04/21 Pt reports fatigue but feels better 08/05/21 Pt reports she is improving every day 08/08/21 Pt continues oxygen use and reports desatting at night along with trouble breathing when she lays down due to stuffiness 08/09/21 Pt reports shoulder pain with no radiation, is sleeping better, and cough is now intermittent 08/11/21 Pt reports slight muscle pain 08/12/21 Pt reports dry cough with intermittent episodes of phlegm, ongoing fatigue, and muscle pain 08/14/21 Pt reports no symptoms; clinically resolved
Pain in arm, upper body aches, back, neck, shoulder, headache sore throat, congestion.
Patient came in for WCC and 6 month vaccinations. The patient was given a pentacel that contains DTAP, HIB, IPV. and a single dose of HIB resulting in double vaccination of HIB. This error was discovered when putting vaccine in system on 04/18/2022. Mother was notified  of vaccine error and stated patient has  had no adverse reactions.. Dr. and Clinic Supervisor made aware of.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 40-year-old female patient received BNT162b2 (BNT162B2), on 05Sep2021 at 11:00 as dose 1, single (Lot number: FD8448) at the age of 40 years, in right arm for Covid-19 immunisation. The patient's relevant medical history included: "syringomyelia" (unspecified if ongoing); "Muscle weakness" (ongoing); "Anxiety" (ongoing); "Pain" (ongoing); "Stomach" (ongoing), notes: Verbatim :Stomach. Concomitant medication(s) included: BACLOFEN oral taken for muscle relaxant therapy (ongoing); XANAX oral taken for anxiety (ongoing); TYLENOL oral taken for pain (ongoing); PROTONIX [OMEPRAZOLE] oral taken for abdominal discomfort (ongoing). The following information was reported: HYPOAESTHESIA (disability, medically significant) with onset 2021, outcome "not recovered", described as "numbness feet". The event "numbness feet" required physician office visit. It was unknown if therapeutic measures were taken as a result of hypoaesthesia. Clinical course: Prior vaccination reported as none. No follow-up attempts are possible. No further information is expected.
death I61.9 - Nontraumatic intracerebral hemorrhage, unspecified R29.810 - Facial weakness I63.9 - Cerebrovascular accident (CVA), unspecified mechanism (CMS/HCC)
Shingles; This is a spontaneous report from a non-contactable consumer, the patient. A 39-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 16Apr2021 at 16:30 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. On 18Sep2020, the patient underwent nasal swab test for COVID-19 and the result was negative. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 19Mar2021 at 16:00 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Apr2021, the patient experienced shingles. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of shingles and included unspecified treatment. The clinical outcome of the event shingles was recovering at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Mom came in, concerned that area was red and he was crawling instead of walking on 10/15/03. Today he came into clinic with slight limping. Redness is improved today. Advised Ibuprofen and observing. If worsens to return per MD.
36 hrs after redness, warmth & soreness at site; 36 hrs after redness, warmth & soreness at site; 36 hrs after redness, warmth & soreness at site; Muscle/body aches; Muscle/body aches; Fatigue; Fever >102 F/ fever 99-100.5 F; Injection site flat macular red rash 7 x 17 cm, thatremains warm to touch, not painful; Generalized pruritus; Injection site flat macular red rash 7 x 17 cm, thatremains warm to touch, not painful; This is a spontaneous report from a contactable nurse, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 30130BA) via an unspecified route of administration in the left arm on 13Sep2021 at 07:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included unspecified multi-history and allergy to multi-medications, never vaccines. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medication included prescribed multi medications. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration in the left arm on 16Aug2021 at 07:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. On 14Sep2021 at 19:30, 36 hours after the vaccination, the patient experienced redness, warmth and soreness at site and fever of greater than 102 Fahrenheit, muscle/body aches and fatigue. Reportedly, 48 hours (15Sep2021) after the vaccination and reoccurring every evening since vaccine, the patient experienced fever 99-100.5 Fahrenheit, generalized pruritus and injection site flat macular red rash 7 x 17 cm, that remained warm to touch but not painful. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events and included treatment with acetaminophen (MANUFACTURER UNKNOWN), from day 2 to through today (at the time of this report) and diphenhydramine hydrochloride (BENADRYL) every bedtime (qhs). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events redness, warmth and soreness at site and fever, muscle/body aches, fatigue, generalized pruritus and injection site flat macular red rash were recovered with lasting effects on an unknown date in Sep2021.
This is a spontaneous report obtained from a contactable Health Care Professional  through a Pfizer sales representative. A patient of an unspecified age, gender, race and ethnicity received PREVNAR 13 on an unknown date, single dose, for immunization. Relevant medical history and concomitant medications were unknown. The patient previously received etanercept (ENBREL) for rheumatoid arthritis and PNEUMOVAX for immunization. On an unspecified date, 7 days after administration of pneumococcal 13-val conj vac (dipht crm197 protein), the patient experienced pain at injection site. Clinical outcome of the event was unknown at time of this report.
vaccination site warmth; vaccination site pruritus; redness on arm around injection site; vaccination site soreness; Vaccination site tenderness; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE WARMTH (vaccination site warmth), VACCINATION SITE PRURITUS (vaccination site pruritus), VACCINATION SITE ERYTHEMA (redness on arm around injection site), VACCINATION SITE PAIN (vaccination site soreness) and VACCINATION SITE PAIN (Vaccination site tenderness) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported.).    On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jan-2021, the patient experienced VACCINATION SITE PAIN (Vaccination site tenderness). On 10-Jan-2021, the patient experienced VACCINATION SITE WARMTH (vaccination site warmth), VACCINATION SITE PRURITUS (vaccination site pruritus), VACCINATION SITE ERYTHEMA (redness on arm around injection site) and VACCINATION SITE PAIN (vaccination site soreness). The patient was treated with CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) ongoing since an unknown date for Allergic reaction, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE WARMTH (vaccination site warmth), VACCINATION SITE PRURITUS (vaccination site pruritus), VACCINATION SITE PAIN (vaccination site soreness) and VACCINATION SITE PAIN (Vaccination site tenderness) was resolving and VACCINATION SITE ERYTHEMA (redness on arm around injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medication include Benadryl, in addition to the Zyrtec she takes every day.
Started feeling dizzy the morning after injection.  Her Blood pressure was up161/96. Dizziness remained all morning, BP did come down to 138/79. She left a message with her PCP and had to call of work for today.
This spontaneous report was received from a nurse referring to an approximately 4 year old patient of unknown gender. Information regarding the patient's pertinent medical history, concurrent conditions, known allergies and concomitant medications was not reported. On 19-DEC-2016, the patient was vaccinated with an expired dose of PNEUMOVAX23 with lot # K009874 and expiration date on 19-MAR-2016 (anatomical route of vaccination was not provided) for prophylaxis. Furthermore, no adverse event was reported and no product quality issue was involved. Additional information has been requested.
I got shingles within a week of getting the 1st pfizer vaccination; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729, expiration date: an unknown date in Jul2021) via an unspecified route of administration in the left arm on 12Apr2021 at 16:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medications within two weeks of vaccination. On 19Apr2021 at 00:00, within a week of getting the 1st Pfizer vaccination, the patient got shingles. The adverse event resulted in emergency room/department or urgent care. Therapeutic measures were taken as a result of the reported event which included treatment with valaciclovir (VALACYCLOVIR) and tramadol (MANUFACTURER UNKNOWN). Since the vaccination, the patient had been tested for COVID-19. On 03Jul2021, the patient underwent SARS-COV-2 test (polymerase chain reaction (PCR)) and the result was negative. The clinical outcome of the event shingles was resolved on an unknown date in 2021. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0172, expiration date: an unknown date in Aug2021) via an unspecified route of administration in the left arm on 03May2021 at 16:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation.
Information has been received from a pharmacist concerning a 60 year old female patient, who on 24-SEP-2012 was vaccinated with the first dose of ZOSTAVAX, subcutaneously, 0.65ml, lot # reported as 0566AE (expiry 01-APR-2013). It was reported that, on 25-SEP-2012, the patient developed "a rash into the armpit". The rash was treated with BENADRYL. The patient did not seek medical attention. At the time of the report, the patient's outcome was not recovered. Additional information has been requested.
Swelling redness and heat at site, applied ice 1st 24 hrs then heat also placed on Benadry. 2.5 inches x 2.5 inches. Red indurated swollen hot.
pt recv vax 25JUN95 11AM & exp hives by 5PM w/severe itching; saw MD on DPH 30AUG95 states will not be receiving #3 Hep B
Information has been received from a physician concerning an approximately 14 year old female who was vaccinated with the first 0.5 ml dose of GARDASIL, VARIVAX (Merck) and hepatitis A vaccine (manufacturer unknown) a few weeks ago.  She was told to wait in the lobby for 15 minutes before she was supposed to leave.  While walking to the lobby the patient fainted.  No injuries occurred.  No lot number was provided.  The patient was recovered few weeks ago.  The patient sought medical attention.  Additional information has been requested.
A week after injection I developed vertigo and lightheadedness I went to my ENT Dr. my ears are fine went to my medical doctor and he diagnosed me with vertigo and recommended that I didn't get the second vaccine or at least postpone it
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 06-AUG-2018, the patient was vaccinated with an improperly stored dose of ROTATEQ, lot # R003114, expiration date 27-SEP-2019 (dose and route of administration were not reported). There was no adverse effect reported. Administered dose of vaccine experienced the temperature excursion of 74 degrees Fahrenheit for 72 hours. Data logger was not involved. There were no previous excursions reported. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1808USA003367.
stroke; This is a spontaneous report from a contactable consumer. An 84-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration, administered in Arm Left on 07Feb2021 10:00 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. Medical history included high blood pressure. The patient has no known allergies and no covid prior vaccination. Concomitant medications included clopidogrel bisulfate, amlodipine, vitamin d [vitamin d nos] and "levoth" (as reported). The patient has no other vaccine in four weeks. On 21Feb2021 at 12 AM, the patient had a bad stroke "14 days" after he's first shot. They think it's the vaccine. The event resulted in hospitalization for 25 days and disability or permanent damage. The patient was covid tested post vaccination via nasal swab on 17Mar2021 which was negative. The outcome of the event was not recovered.  Information on the Lot/batch number has been requested.
This case was reported by a consumer via call center representative and described the occurrence of shingles in a 72-year-old female patient who received SHINGRIX for prophylaxis. The patient's past medical history included shingles (repeated episodes of shingles). Concurrent medical conditions included osteoarthritis and neuropathy (in back due to continuous episodes of shingles). In December 2018, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. In January 2019, less than a month after receiving SHINGRIX, the patient experienced throbbing pain, nerve pain and pain in thigh. On an unknown date, the patient experienced shingles and rash. On an unknown date, the outcome of the shingles, throbbing pain, rash, nerve pain and pain in thigh were unknown. It was unknown if the reporter considered the shingles, throbbing pain, rash, nerve pain and pain in thigh to be related to SHINGRIX. Additional details were reported as follows: The patient received SHINGRIX vaccine on left arm approximately four weeks before the date of reporting. One week before the date of reporting the patient developed shingles on her left hip along her panty line. There were approximately 5 to 6 bumps. The patient had throbbing nerve pain that radiated down in to her left thigh last night, causing her to not be able to sleep. She is still experiencing pain today but it is a little less than during the night. The reporter consented to follow up. The reporter gave permission for her physician to be contacted.
Erythema, pain, itching at site L deltoid with 7x12 cm of blotchy erythema, increased heat.
2 inch diameter circular erythema and edema at injection point that began 14 Aug 2021
Soreness (pain!!!) when using left arm (where inj. site was)- esp. when using arm to pull, when crossing in front of chest, and when lifting arms to dress or undress. Inj. 11-19-09. Today is 12-9-09 also left upper shoulder 'Knots' in back.
Slight redness and itching. Could be from the bandaid. Reacted to a bandaid last year after a reg flu shot.